Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERIDONE vs ABILIFY MAINTENA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Schizophrenia,Bipolar I disorder (acute manic or mixed episodes),Irritability associated with autistic disorder,Adjunctive therapy in major depressive disorder,Tourette syndrome (off-label),Obsessive-compulsive disorder (off-label)
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Extensively metabolized in the liver via CYP2D6 and CYP3A4 to 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The parent drug and metabolite are equally active.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Risperidone: 90% bound to albumin and alpha-1-acid glycoprotein; 9-hydroxyrisperidone: 77% bound
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Risperidone: 1-2 L/kg; 9-hydroxyrisperidone: 0.5-1 L/kg; extensive tissue distribution
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Oral: 70% (tablet), 70% (oral solution); intramuscular: 100% for immediate-release, 28% for long-acting injection relative to oral
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: initiate at 0.5 mg orally twice daily for at least 1 week, then increase by 0.5 mg twice daily as tolerated; maximum 3 mg/day.
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
Child-Pugh Class A or B: initiate at 0.5 mg orally twice daily, increase cautiously. Class C: avoid or use with extreme caution; no specific established dose.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Adolescents (13-17 yr) with schizophrenia: initial 0.5 mg orally once daily, titrate to 3 mg/day as tolerated. Children (10-17 yr) with bipolar mania: initial 0.5 mg once daily, titrate to 1-2.5 mg/day. Weight-based not standard; use fixed dosing.
Not approved for pediatric use.
Initiate at 0.5 mg orally once daily; increase by 0.5 mg/day increments; target dose 1-2 mg/day; monitor for orthostasis and extrapyramidal symptoms.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (stroke, TIA) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,QT interval prolongation,Priapism,Dysphagia,Body temperature dysregulation,Potential for cognitive and motor impairment
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Hypersensitivity to risperidone or any component of the formulation
Hypersensitivity to aripiprazole or any excipients in the formulation.
Avoid grapefruit and grapefruit juice; may increase risperidone plasma concentrations. Alcohol can potentiate CNS depression and increase risk of side effects. No specific food restrictions; take with or without food. High-fat meals may slightly increase absorption.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposure may cause neonatal extrapyramidal symptoms (e.g., agitation, hypertonia, tremors) and withdrawal symptoms (e.g., respiratory distress, feeding difficulties).
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Risperidone is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5 for the parent drug and 0.3 for the active moiety (risperidone + 9-hydroxyrisperidone). Relative infant dose (RID) is about 2-4% of the maternal weight-adjusted dose. Monitor the infant for sedation, poor feeding, and extrapyramidal effects. The benefit of breastfeeding should be weighed against potential risks.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
Increased clearance of risperidone in pregnancy may require dose adjustments. Some studies suggest a dose increase of 20-30% during the second and third trimesters to maintain therapeutic levels. TDM is recommended to guide dosing, with target trough concentrations similar to non-pregnant patients (10-20 ng/m L for the active moiety). Postpartum dose should be reduced to pre-pregnancy levels.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Monitor for orthostatic hypotension, especially during dose titration. Risperidone can cause QTc prolongation; obtain baseline ECG in at-risk patients. Extrapyramidal symptoms (EPS) are dose-dependent; use lowest effective dose. In elderly dementia patients, increased risk of cerebrovascular events; not approved for this indication. Prolactin elevation is common; monitor for gynecomastia, galactorrhea, and sexual dysfunction. Taper slowly to avoid withdrawal dyskinesia.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Take risperidone exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol and grapefruit juice as they may affect drug levels and increase side effects.,Rise slowly from sitting or lying down to prevent dizziness from low blood pressure.,Report any involuntary muscle movements, restlessness, or stiffness to your healthcare provider.,Notify your doctor if you experience breast swelling, discharge, or sexual problems.,Do not drive or operate heavy machinery until you know how risperidone affects you.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
"Carvedilol, a nonselective beta-blocker with alpha1-blocking activity, may enhance the hypotensive effects of risperidone, an atypical antipsychotic with alpha1-adrenergic antagonism. This additive pharmacodynamic interaction can lead to exaggerated blood pressure reduction, orthostatic hypotension, dizziness, and increased risk of syncope, particularly during initial dosing or dose titration. Patients with cardiovascular comorbidity or volume depletion are at heightened risk for adverse outcomes such as falls or cardiac ischemia."
"Cilazapril, an angiotensin-converting enzyme inhibitor (ACEI), reduces angiotensin II production and aldosterone secretion, leading to vasodilation and decreased blood pressure. Risperidone, an atypical antipsychotic, can cause orthostatic hypotension through alpha-1 adrenergic receptor blockade. Concurrent use may result in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope, particularly at treatment initiation or dose adjustments."
"Coadministration of risperidone and pizotifen may lead to additive anticholinergic and sedative effects due to their overlapping pharmacological profiles. Risperidone, an atypical antipsychotic with histamine H1 receptor antagonist properties, combined with pizotifen, a serotonin antagonist with strong anticholinergic and antihistaminergic activity, can result in excessive sedation, cognitive impairment, and peripheral anticholinergic effects such as dry mouth, constipation, and urinary retention. Clinically, this interaction increases the risk of falls, confusion, and reduced functional status, especially in elderly patients or those with pre-existing central nervous system depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERIDONE vs ABILIFY MAINTENA KIT, answered by our medical review team.
RISPERIDONE is a Atypical Antipsychotic that works by Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.. ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERIDONE and ABILIFY MAINTENA KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERIDONE is: Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.. The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERIDONE and ABILIFY MAINTENA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERIDONE is classified as Category A/B. Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposu. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.